ReviewJournal of clinical medicine2026
Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antithrombotic therapy management in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains challenging as it requires simultaneous protection from cardioembolism and coronary ischemic events while minimizing bleeding. The coexistence of these competing risks, along with their different temporal profiles, has driven a major shift in therapeutic strategies over the past decade. Randomized trials have consistently shown that direct oral anticoagulant (DOAC)-based dual antithrombotic therapy (DAT) reduces bleeding as compared with prolonged triple antithrombotic therapy (TAT), supporting early aspirin withdrawal in most patients. At the same time, pooled analyses suggest that this simplification may be accompanied by a small increase in ischemic risk, particularly during the first month after PCI, when the hazard of stent thrombosis is the highest. Contemporary guideline recommendations from Europe and North America are now broadly aligned in favoring a short periprocedural course of TAT followed by DAT with a DOAC and clopidogrel, then transitioning to oral anticoagulant monotherapy. However, important uncertainty remains for patients with very high ischemic or bleeding risk, including those with acute coronary syndromes, complex PCI, prior stent thrombosis, frailty, chronic kidney disease, previous bleeding, or active cancer. In these settings, treatment decisions cannot rely solely on trial-derived estimates or isolated risk scores, but require individualized, dynamic, and phase-specific assessments. This review critically appraises the biologic rationale, randomized evidence, and contemporary guideline recommendations for antithrombotic therapy in patients with AF undergoing PCI, focusing on areas not fully resolved by current guidelines, including modulation strategies, high-risk and underrepresented populations, tailored antithrombotic management, and emerging therapeutic directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.